Allakos Inc (ALLK)
0.7467
-0.01
(-1.75%)
USD |
NASDAQ |
Jul 05, 16:00
0.7467
0.00 (0.00%)
After-Hours: 17:02
Allakos SG&A Expense (TTM): 44.08M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 44.08M |
December 31, 2023 | 45.15M |
September 30, 2023 | 44.79M |
June 30, 2023 | 46.34M |
March 31, 2023 | 50.47M |
December 31, 2022 | 57.35M |
September 30, 2022 | 69.73M |
June 30, 2022 | 75.78M |
March 31, 2022 | 77.32M |
December 31, 2021 | 75.15M |
September 30, 2021 | 67.76M |
June 30, 2021 | 60.76M |
March 31, 2021 | 56.61M |
Date | Value |
---|---|
December 31, 2020 | 51.52M |
September 30, 2020 | 45.97M |
June 30, 2020 | 41.43M |
March 31, 2020 | 35.32M |
December 31, 2019 | 29.56M |
September 30, 2019 | 23.77M |
June 30, 2019 | 19.53M |
March 31, 2019 | 15.96M |
December 31, 2018 | 12.43M |
September 30, 2018 | 9.347M |
June 30, 2018 | 6.978M |
March 31, 2018 | 5.443M |
December 31, 2017 | 3.748M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
23.77M
Minimum
Sep 2019
77.32M
Maximum
Mar 2022
52.57M
Average
50.47M
Median
Mar 2023
SG&A Expense (TTM) Benchmarks
Tonix Pharmaceuticals Holding Corp | 36.67M |
RAPT Therapeutics Inc | 27.81M |
NovaBay Pharmaceuticals Inc | 12.53M |
Palatin Technologies Inc | 13.34M |
iBio Inc | 11.84M |